NDAORALTABLET
Approved
Nov 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATTRUBY (acoramidis hydrochloride) is an oral small-molecule tablet approved by the FDA on November 22, 2024. The mechanism of action and therapeutic indication are not publicly detailed in available data, but the drug is positioned in early growth phase by BridgeBio Pharma. It represents a novel chemical entity in the company's pipeline with a 13.3-year patent exclusivity window.
Growth13.3 years to LOE
Early-stage growth product with significant team expansion anticipated as commercial infrastructure scales and market penetration accelerates.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
BridgeBio Pharma is hiring 10 roles related to this product
Worked on ATTRUBY at BridgeBio Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.